Context Therapeutics (CNTX) Competitors $0.81 +0.02 (+2.41%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.82 +0.01 (+1.11%) As of 02/21/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CNTX vs. ALMS, ZYBT, LFVN, VYGR, DSGN, FDMT, LFCR, CCCC, CRDF, and SLRNShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Alumis (ALMS), Zhengye Biotechnology (ZYBT), LifeVantage (LFVN), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Alumis Zhengye Biotechnology LifeVantage Voyager Therapeutics Design Therapeutics 4D Molecular Therapeutics Lifecore Biomedical C4 Therapeutics Cardiff Oncology Acelyrin Context Therapeutics (NASDAQ:CNTX) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk. Do analysts recommend CNTX or ALMS? Context Therapeutics presently has a consensus price target of $6.33, suggesting a potential upside of 682.86%. Alumis has a consensus price target of $26.57, suggesting a potential upside of 413.95%. Given Context Therapeutics' higher possible upside, equities research analysts plainly believe Context Therapeutics is more favorable than Alumis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media refer more to CNTX or ALMS? In the previous week, Alumis had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Alumis and 2 mentions for Context Therapeutics. Alumis' average media sentiment score of 0.70 beat Context Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is CNTX or ALMS more profitable? Alumis' return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -58.76% -55.80% Alumis N/A N/A N/A Do insiders & institutionals believe in CNTX or ALMS? 14.0% of Context Therapeutics shares are owned by institutional investors. 3.0% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, CNTX or ALMS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$23.96M-$0.91-0.89AlumisN/AN/AN/AN/AN/A Does the MarketBeat Community favor CNTX or ALMS? Context Therapeutics received 6 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 75.00% of users gave Context Therapeutics an outperform vote. CompanyUnderperformOutperformContext TherapeuticsOutperform Votes2175.00% Underperform Votes725.00% AlumisOutperform Votes15100.00% Underperform VotesNo Votes SummaryAlumis beats Context Therapeutics on 8 of the 12 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.25M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.895.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book1.096.717.644.62Net Income-$23.96M$138.33M$3.18B$245.85M7 Day Performance-1.53%-2.61%-1.99%-2.68%1 Month Performance-13.73%-2.32%-0.42%-2.19%1 Year Performance-30.26%-5.31%16.51%12.84% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics1.2694 of 5 stars$0.81+2.4%$6.33+682.9%-32.6%$59.25MN/A-0.897News CoverageGap UpALMSAlumisN/A$5.21+2.2%$26.57+410.0%N/A$246.02MN/A0.00N/ANews CoverageZYBTZhengye BiotechnologyN/A$4.99+1.0%N/AN/A$235.38MN/A0.00278Quiet Period ExpirationGap DownLFVNLifeVantage4.1084 of 5 stars$18.56+0.7%$30.50+64.3%+139.1%$232.93M$200.16M33.14260VYGRVoyager Therapeutics4.5304 of 5 stars$4.23-3.4%$15.72+271.5%-44.8%$231.09M$250.01M5.96100Upcoming EarningsNews CoverageDSGNDesign Therapeutics1.7847 of 5 stars$4.08+2.8%$7.00+71.6%+81.2%$231.01MN/A-4.8040FDMT4D Molecular Therapeutics3.1324 of 5 stars$4.88+3.4%$32.13+558.3%-82.5%$225.60M$20.72M-1.71120Analyst ForecastLFCRLifecore Biomedical2.6544 of 5 stars$6.09+2.5%$8.00+31.4%-30.1%$225.51M$128.26M-10.88690CCCCC4 Therapeutics2.7355 of 5 stars$3.18-0.6%$11.60+264.8%-58.5%$224.48M$20.76M-1.87150News CoverageCRDFCardiff Oncology2.2196 of 5 stars$4.29+3.4%$10.33+140.9%+182.7%$219.35M$490,000.00-4.5620News CoverageSLRNAcelyrin2.8673 of 5 stars$2.13+3.4%$9.60+350.7%-66.0%$213.70MN/A-0.87135News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies ALMS Alternatives ZYBT Alternatives LFVN Alternatives VYGR Alternatives DSGN Alternatives FDMT Alternatives LFCR Alternatives CCCC Alternatives CRDF Alternatives SLRN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 financial crisis over a year in advance. His readers had a chance to lock in g...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
